25 CHF CHF 25.00
AG-CR1-3589-M02525 mgCHF 25.00
AG-CR1-3589-M100100 mgCHF 60.00
AG-CR1-3589-M500500 mgCHF 240.00
|Synonyms||MK 906; L-652,931; BRN 4269024|
|Merck Index||14: 4082|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO, DMF, ethanol or methanol. Sparingly soluble in water.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||+4°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 2 years after receipt when stored at +4°C.|
|Product Specification Sheet|
- Potent, specific and competitive inhibitor of type II 5α-reductase (enzyme which converts testosterone to the more potent 5α-dihydrotestosterone) [1, 3].
- Anticancer compound [2, 6, 7].
- Apoptosis modulator [2, 6].
- Enhances the action of GABA at GABA(A) receptors, which leads to neurological implications .
- Inhibit testosterone-induced type I procollagen and TGF-β1 expression in human scalp dermal fibroblasts in a model of androgenic alopecia .
- Drug for the treatment of male androgenetic alopecia .
- Potential role in neuropsychiatric disorders .
- Shown to reduce L-DOPA-induced dyskinesia in rodent models for Parkinson’s disease .
- Finasteride: the first 5 alpha-reductase inhibitor: S.L. Sudduth & M.J. Koronkowski; Pharmacotherapy 13, 309 (1993)
- Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins: H. Huynh; Int. J. Oncol. 20, 1297 (2002)
- Steroid 5α-reductase inhibitors: R. Flores, et al.; Mini Rev. Med. Chem. 3, 225 (2003)
- A new look at the 5alpha-reductase inhibitor finasteride: D.A. Finn, et al.; CNS Drug Rev. 12, 53 (2006)
- Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia; H.G. Yoo, et al.; Biol. Pharm. Bull. 29, 1246 (2006)
- Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008)
- Molecular profiles of finasteride effects on prostate carcinogenesis: Cancer Prev. Res. 2, 518 (2009)
- Male androgenetic alopecia: D. Rathnayake & R. Sinclair; Expert Opin. Pharmacother. 11, 1295 (2010)
- Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders: S. Paba, et al.; Curr. Pharm. Des. 17, 151 (2011)
- 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction: S. Fanni, et al.; Neurobiol. Dis. 121, 120 (2018)